GSK Delivers Q3 Beat, yet Market Questions Path Beyond Patent Cliff
GSK beat Q3 sales and profit forecasts on strong specialty medicines, but shares fell as investors questioned the pipeline and restructuring.
GSK beat Q3 sales and profit forecasts on strong specialty medicines, but shares fell as investors questioned the pipeline and restructuring.
Ionis’s bepirovirsen (Hibsago) is now FDA-approved for chronic hepatitis B. The six-month treatment achieved functional cure in up to 26% of patients, far above standard care.
FDA grants accelerated approval to Jemperli for stage II/III MSI-H/dMMR rectal cancer, sending AnaptysBio stock higher on royalty potential.
Wave plans a single two-year trial for WVE-006 in AATD after FDA feedback, with a one-year review for possible accelerated approval.
GSK will buy a Chimagen trispecific T-cell engager for multiple myeloma. Phase I trials start in 2027. The deal is worth up to $750 million.
Jideytro shrank tumors in 94% of untreated ROS1 patients; Ris-Rez cut death risk 54% vs topotecan in China. FDA filing planned this year.